ATXI: Avenue Therapeutics, Inc. Stock

by  •  • Comments Off on ATXI: Avenue Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.81
Enterprise Value ($M) 0.10
Book Value ($M) 0.65
Book Value / Share 1.11
Price / Book 4.30
NCAV ($M) 0.65
NCAV / Share 1.11
Price / NCAV 4.30

Profitability (mra)
Return on Invested Capital (ROIC) -15.87
Return on Assets (ROA) -1.23
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.55
Current Ratio 1.55

Balance Sheet (mrq) ($M)
Current Assets 1.85
Assets 1.85
Liabilities 1.20
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -14.54
Net Income -10.38
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -9.45
Cash from Investing -3.00
Cash from Financing 7.53

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G/A Davidow Robert L 2.90 -98.69
04-17 13D/A Fortress Biotech, Inc. 8.00 239.74
01-02 13G/A Sabby Management, Llc 4.99 150.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 5,658 28,074 20.15
2024-05-01 15,043 54,005 27.85
2024-04-30 48,484 147,476 32.88
2024-04-29 42,437 52,248 81.22

(click for more detail)

Similar Companies
ASRT – Assertio Holdings, Inc. ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc. AVTX – Avalo Therapeutics, Inc.
AWH – Aspira Women's Health Inc.


Financial data and stock pages provided by
Fintel.io